Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response.

ABSTRACT:

Background

Bispecific T-cell engagers (BiTEs) are recombinant bispecific proteins designed to stimulate polyclonal T-cell immunity. In recent years, B7H3, a pan-cancer antigen, has been considered a promising target for future immunotherapy. However, the B7H3-targeting BiTE faces the challenge of systemic toxicity. Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics and serve as an appropriate platform for locoregional delivery of therapeutic genes. In this study, we designed an oncolytic adenovirus (OAd) encoding BiTE targeting human B7H3. We hypothesized that OVs encoding B7H3 BiTE deliver this molecule persistently to the tumor site while mediating polyclonal T-cell activation and redirecting it to tumor cells.

Methods

B7H3-targeting BiTE was constr

SUBMITTER: Zhu H 

PROVIDER: S-EPMC11624812 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature